Document Detail

New role for L-arginine in regulation of inducible nitric-oxide-synthase-derived superoxide anion production in raw 264.7 macrophages.
Jump to Full Text
MedLine Citation:
PMID:  22219714     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dietary supplementation with L-arginine was shown to improve immune responses in various inflammatory models. However, the molecular mechanisms underlying L-arginine effects on immune cells remain unrecognized. Herein, we tested the hypothesis that a limitation of L-arginine could lead to the uncoupled state of murine macrophage inducible nitric oxide synthase and, therefore, increase inducible nitric-oxide-synthase-derived superoxide anion formation. Importantly, we demonstrated that L-arginine dose- and time dependently potentiated superoxide anion production in bacterial endotoxin-stimulated macrophages, although it did not influence NADPH oxidase expression and activity. Detailed analysis of macrophage activation showed the time dependence between LPS-induced iNOS expression and increased O(2)(∙-) formation. Moreover, downregulation of macrophage iNOS expression, as well as the inhibition of iNOS activity by NOS inhibitors, unveiled an important role of this enzyme in controlling O(2)(∙-) and peroxynitrite formation during macrophage stimulation. In conclusion, our data demonstrated that simultaneous induction of NADPH oxidase, together with the iNOS enzyme, can result in the uncoupled state of iNOS resulting in the production of functionally important levels of O(2)(∙-) soon after macrophage activation with LPS. Moreover, we demonstrated, for the first time that increased concentrations of L-arginine further potentiate iNOS-dependent O(2) (∙-) formation in inflammatory macrophages.
Authors:
Michaela Pekarova; Antonin Lojek; Hana Martiskova; Ondrej Vasicek; Lucia Bino; A Klinke; D Lau; Radek Kuchta; Jaroslav Kadlec; Radimir Vrba; Lukas Kubala
Related Documents :
9560294 - Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediat...
22219714 - New role for l-arginine in regulation of inducible nitric-oxide-synthase-derived supero...
10616034 - Vascular nitric oxide, sex hormone replacement, and fish oil may help to prevent alzhei...
11713354 - Repeatability of cellular constituents and cytokine concentration in fluid obtained by ...
18788084 - Distinctly different expression of cytokines and chemokines in the lungs of two h5n1 av...
24375944 - Immune response to chemically modified proteome.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-12-18
Journal Detail:
Title:  TheScientificWorldJournal     Volume:  11     ISSN:  1537-744X     ISO Abbreviation:  ScientificWorldJournal     Publication Date:  2011  
Date Detail:
Created Date:  2012-01-05     Completed Date:  2012-04-17     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101131163     Medline TA:  ScientificWorldJournal     Country:  England    
Other Details:
Languages:  eng     Pagination:  2443-57     Citation Subset:  IM    
Affiliation:
Institute of Biophysics, The Academy of Sciences of Czech Republic, Kralovopolska 135, 612 65 Brno, Czech Republic. pekarovam@ibp.cz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arginine / immunology*
Biopterin / analogs & derivatives,  metabolism
Cell Line
Cell Survival
Enzyme Activation
Enzyme Inhibitors / pharmacology
Escherichia coli / immunology
Lipopolysaccharides / adverse effects
Macrophages / drug effects,  immunology*,  metabolism
Mice
NADPH Oxidase / metabolism
NG-Nitroarginine Methyl Ester / pharmacology
Nitric Oxide / metabolism
Nitric Oxide Synthase Type II / antagonists & inhibitors,  metabolism*
Respiratory Burst
Superoxides / metabolism*
Time Factors
Tyrosine / analogs & derivatives,  metabolism
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Lipopolysaccharides; 10102-43-9/Nitric Oxide; 11062-77-4/Superoxides; 17528-72-2/5,6,7,8-tetrahydrobiopterin; 22150-76-1/Biopterin; 3604-79-3/3-nitrotyrosine; 50903-99-6/NG-Nitroarginine Methyl Ester; 55520-40-6/Tyrosine; 74-79-3/Arginine; EC 1.14.13.39/Nitric Oxide Synthase Type II; EC 1.6.3.1/NADPH Oxidase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): ScientificWorldJournal
Journal ID (publisher-id): TSWJ
ISSN: 1537-744X
Publisher: TheScientificWorldJOURNAL
Article Information
Download PDF
Copyright © 2011 Michaela Pekarova et al.
open-access:
Received Day: 9 Month: 9 Year: 2011
Accepted Day: 7 Month: 11 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 18 Month: 12 Year: 2011
Volume: 11First Page: 2443 Last Page: 2457
ID: 3246759
PubMed Id: 22219714
DOI: 10.1100/2011/321979

New Role for L-Arginine in Regulation of Inducible Nitric-Oxide-Synthase-Derived Superoxide Anion Production in Raw 264.7 Macrophages
Michaela Pekarova1*
Antonin Lojek1
Hana Martiskova1, 2I2
Ondrej Vasicek1
Lucia Bino1
A. Klinke3
D. Lau3
Radek Kuchta4
Jaroslav Kadlec4
Radimir Vrba4
Lukas Kubala1
1Institute of Biophysics, The Academy of Sciences of the Czech Republic, Kralovopolska 135, 612 65 Brno, Czech Republic
2Department of Biochemistry, Faculty of Science, Masaryk University, Kotlarska 267/2, 611 37 Brno, Czech Republic
3Department of Cardiology, Hamburg University Heart Center, Martinistrasse 52, 20246 Hamburg, Germany
4Faculty of Electrical Engineering and Communication, Brno University of Technology, Technicka 3058/10, 616 00 Brno, Czech Republic
Correspondence: *Michaela Pekarova: pekarovam@ibp.cz
[other] Academic Editor: Marco Antonio Cassatella

1. INTRODUCTION

The innate immune system provides the first-line defense against injurious insults. Beside its beneficial role in organism defense, deregulation of innate immune responses is implicated in the pathogenesis of various chronic diseases, including congestive heart failure, type 2 diabetes, and associated complications such as dyslipidemia and artherosclerosis [14]. These pathological conditions are believed to be tightly associated with an increased and long-termed synthesis of reactive oxygen (ROS) and reactive nitrogen species (NO; superoxide anion O2; hydrogen peroxide, H2O2; and peroxynitrite, ONOO, etc.) by activated monocytes and macrophages. Particularly ROS are suggested to be responsible for the oxidation of a wide array of molecules in cells, including DNA and proteins that can promote pathological changes in arteries [1, 3, 4].

O2 is the first ROS produced by macrophages upon their contact with a variety of activating stimuli (e.g., LPS, cytokines, growth factors, and fragments of bacterial membranes) [5]. The significant source of O2 in phagosomes during the first hours after stimulation was shown to be the macrophage NADPH oxidase enzyme complex [6, 7]. Another crucial reactive intermediate that is critically involved in the antimicrobial and antitumor activities of macrophages is NO [8]. It is biosynthesized by nitric oxide synthase (NOS) from L-arginine in macrophages activated by proinflammatory stimuli like IFN-γ, TNF, and LPS [810]. The enzyme functions as a dimer consisting of two identical monomers, which can be functionally (and structurally) divided into two major domains: a C-terminal reductase domain and an N-terminal oxygenase domain. Inducible NOS (iNOS) has been described as calcium-insensitive and dependent on the binding of different cofactors like NADPH, flavin adenine dinucleotide, flavin mononuleotide, heme, tetrahydrobiopterine (BH4), and calmodulin [1113]. Interestingly, it was shown previously that, in the absence of L-arginine or NOS cofactors, iNOS isolated from macrophages becomes uncoupled [14, 15]. The uncoupled state of NOS was described when electrons flowing from the reductase domain to the heme are diverted to molecular oxygen instead of to L-arginine, resulting in the formation of O2 [16]. These facts suggest that simultaneous production of O2 (by NADPH oxidase and iNOS enzyme) and NO (by iNOS enzyme) can lead to increased O2 as well as ONOO formation. ONOO, a short-lived oxidant and potent inducer of cell death, is believed to be responsible for the progress of vascular diseases, ischaemia-reperfusion injury, circulatory shock, and inflammation [1, 2, 5].

L-arginine is an abundant amino acid in body fluids which is not toxic to cells [17]. Importantly, it was previously demonstrated that L-arginine has a unique role in the maintenance of immune homeostasis [18, 19]. It was found that it is crucially involved in the regulation of T-cell and macrophage functions [2022] and according to different clinical studies, it is now suggested that L-arginine supplementation may be of clinical benefit in improving wound healing and immune responses in humans [23, 24]. Since, L-arginine is now recognized as influencing the relationships between innate and acquired immune responses, we tested the hypothesis that a limitation of L-arginine could lead to the uncoupled state of iNOS and, therefore, increase iNOS-derived O2 formation. The goal was to describe, in greater detail, the effect of various concentrations of L-arginine on the kinetic of O2 and NO production and to find the possible connection between iNOS protein expression and activity and O2 production in inflammatory macrophages.


2. MATERIAL AND METHODS
2.1. Cell Culture

Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (USA). The murine RAW 264.7 macrophage cell line was obtained from the American Type Culture Collection (ATCC, USA) and was grown in Dulbecco's modified Eagle's media (PAA, Pasching, Austria) supplemented with 10% fetal bovine serum (FBS, low endotoxin; PAA, Pasching, Austria) and 1% gentamycin. Cells were stimulated with 50 ng/mL of LPS (Escherichia coli serotype 026:B6).

For the evaluation of the effect of extracellular L-arginine availability, L-arginine-free DMEM media was used for the experiments. DMEM media was supplemented with different concentrations of L-arginine: 100, 200, 300, and 400 μM, which were chosen according to a few criteria. First, we selected doses that were comparable with reference mammalian plasma values for L-arginine (~36–140 μM) [25], and the highest concentration of L-arginine (400 μM) was comparable with its content in commercially available DMEM media commonly used for in vitro experiments.

The following NOS inhibitors were employed: N-nitro-L-arginine methyl ester (L-NAME; final concentration 25 μM), 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine (AMT; final concentration 10 μM), aminoguanidine (AG; final concentration 10 μM), and L-N6-(1-iminoethyl) lysine (LYS; final concentration 10 μM).

2.2. Cell Viability

The viability of cells was tested based on the total cellular mass of the adherent cells, using detergent-compatible protein assay reagent (Bio-Rad Laboratories, USA), with bovine serum albumin as a standard, as described previously [26]. None of the studied drugs was toxic for RAW 264.7 in the concentrations applied (data not shown).

2.3. Intracellular L-Arginine Concentration

Intracellular L-arginine was determined using a validated high-throughput liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay, described in details elsewhere [27]. Cells were treated in DMEM media without L-arginine or with 400 μM of L-arginine in the absence or presence of LPS (50 ng/mL) for 24 h.

2.4. Western Blot Analysis of iNOS

After the treatment procedure, the RAW 264.7 cells were lysed using SDS-lysing buffer. The same amount of protein (30 μg) from each lysate was subjected to SDS-polyacrylamide gel electrophoresis, as described previously [28]. After electrophoresis, the proteins were transferred to a PVDF (Immobilon-P) membrane and then incubated with a mouse iNOS-specific antibody (1/5000) (Anti-iNOS/NOS Type II mAb, Transduction Laboratories, USA) for 24 h, and with horseradish peroxidase-labelled anti-mouse IgG antibody (1/2000) (ECL Anti-mouse IgG, Biosciences, USA) for 1 h. The equal loading of proteins was verified by β-actin immunoblotting (1/5000, SantaCruz Biotechnology, USA). The blots were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA) and exposed to CP-B X-ray films (Agfa, Czech Republic). The relative levels of the proteins were quantified by scanning densitometry, using the ImageJ program, and the individual band density value was expressed in arbitrary units.

2.5. Determination of Nitrites

NO production was determined based on the accumulation of NO oxidation product nitrites. Nitrite accumulation in cell culture media was determined by Griess method, using sodium nitrite as a standard, as described previously [29].

2.6. Cytochrome c Reduction Assay

The extracellular production of O2 in macrophages was determined via spectrophotometric analysis of cytochrome c reduction as described in details previously [30]. The concentration of superoxide was calculated using the extinction coefficient of reduced cytochrome c.

2.7. Determination of NADPH Oxidase Activity

The NADPH oxidase activity was determined in cell lysates prepared according to the well-established protocol [31]. Briefly, to the 100 μL of tested solution, lucigenin was added at final concentration 5 μM. After that, NADPH at final concentration 100 μM was added to start the production of O2. The luminescence signal was measured for 1 h.

2.8. Detection of NOX2, p47phox, and p67phox Expression by Quantitative RT-PCR

Total RNA was isolated from RAW 264.7 cells with TRIZOL solution (TRI Reagent RT, MRC, USA), according to the supplier's instructions. RNA (1 μg) was reverse transcribed to cDNA according to the manufacturer's instructions (DyNAmo cDNA Synthesis Kit, Finnzymes, Finland). The primers and probe no. 20 for NOX2, p67phox, and p47phox were designed using the Universal Probe Library (Roche, Switzerland). The sequence of primers was as follows: NOX2 (forward 5′-gtgcacagcaaagtgattgg-3′, reverse 5′-tgccaacttcctcagctaca-3′), p47phox (forvard 5′-ctgccacttaaccaggaacat-3′, reverse 5′-ggacaccttcattcgccata-3′), and p67phox (forvard 5′-ccagccattcttcattcaca-3′, reverse 5′-cccaggtggtagcaatcttc-3′). Real-time PCR was performed on RTCykler7300 (Applied Biosystems), and the parameters of amplification were set up according to the supplier's instructions. The fold of the mRNA induction was calculated using the ΔΔCt method, with GAPDH as a housekeeping gene (TaqMan Rodent GAPDH Control reagent, Applied Biosystems, USA) [31].

2.9. Transfection of RAW 264.7 Cells

Using an electroporation system (Gene Pulser II, Bio-Rad laboratopries, USA, for details see [31]), cells were transfected with plasmids containing the shRNA construct, against iNOS and negative control plasmid with a scrambled sequence (Origene, USA). Stably transfected cells were grown in DMEM + 5% FBS and 5 μg/mL puromycin. RAW 264.7 cells transfected with both shRNA and negative control plasmid were sensitive to LPS stimulation. In the case of LPS-activated RAW 264.7 cells transfected with negative control plasmid, the expression of iNOS protein, nitrite accumulation, and O2 production were comparable with those measured for nontransfected LPS-activated RAW 264.7 cells (data not shown).

2.10. Luminol-Enhanced Chemiluminescence (CL) Determination of Oxidative Burst

The CL of macrophages was measured using a microplate luminometer LM-01T (Immunotech, Czech Republic), as described previously [32]. Briefly, the reaction mixture consisted of 100 μL of cells (100 × 105), 1 mM luminal, and one of the oxidative burst activators (PMA, 97.6 μg/mL or opsonized zymosan particles (OZP), 0.4 mg/mL). Spontaneous CL measurements in samples containing the macrophages and all other substances, but none of the activators, were included in each assay. The CL emission was followed for 2 h at 37°C. The integral value of the CL reaction represents the total ROS production by macrophages.

2.11. Immunocytochemistry

This method was used for the evaluation of NO- and O2-derived ONOO, which is known to react with tyrosine residues on proteins and yields a specific nitration product, nitrotyrosine [14]. Briefly, after treatment on 98-well plates (PAA), cells were fixed with 4% of paraformaldehyde in PBS at room temperature for 30 min. Cells were then incubated with mouse monoclonal antinitrotyrosine IgG (1 : 500, Upstate Biotechnology, USA) for 1 h. The immunostaining was accomplished with an Extravidin peroxidase staining kit using 3-amino-9-ethylcarbazole as a chromogen. The cells were then photographed under a light microscope at ×200 magnification.

2.12. Detection of Scavenging Properties of Drugs against NO

The potential ability of drugs to scavenge NO in chemical systems was tested by the electrochemical measurement of NO, as described previously [28]. The scavenging properties of the tested drugs are represented as a very rapid decrease in NO-induced signal detected by electrode connected to ISO NO MARK II potentiostat (WPI, USA). The integral area under the resulting curve corresponded to the total amount of NO present in the glass vial and was used for the evaluation of scavenging properties of the tested drugs. The scavenging properties of the drugs and chemicals against NO were not significant (data not shown).

2.13. Data Analysis

Data were statistically analyzed using a one-way analysis of variance (ANOVA), which was followed by Dunnett's multiple comparison test (Statistica for Windows 8.0, Statsoft, Tulsa, Okla, USA). All data are reported as means ± SEM. A P value of less than 0.05 was considered significant.


3. RESULTS
3.1. L-Arginine-Enhanced Production of O2 in RAW 264.7 Macrophages Stimulated with LPS

In the first set of experiments, we tested the established hypothesis that a limitation of L-arginine availability could lead to the uncoupled state of iNOS and, therefore, increase iNOS-derived O2 formation. Surprisingly, we found that, during the time of RAW 264.7 cells incubation with LPS, L-arginine, in all concentrations used (100–400 μM), caused a marked dose- and time-dependent increase in O2 formation, which started to rise after 12 h of cell incubation with LPS (Figure 1). In comparison to RAW 264.7 cells incubated in DMEM without L-arginine supplementation, the intracellular concentration of L-arginine was significantly increased after 24 h of cell treatment with 400 μM of L-arginine (38.91 ± 3.18 μM and 71.50 ± 3.25 μM*, mean ± SEM), as was determined by the specific LC-MS/MS method.

3.2. Time-Dependent Induction of iNOS Protein, NO Production, and O2 Formation in LPS-Stimulated RAW 264.7 Cells

The marked increase in O2 production in LPS-stimulated macrophages led to questions regarding the origin of the O2 that was produced during the experiments. Therefore, we measured the iNOS protein expression, nitrite accumulation, and also the O2 formation during a time period of 24 h after LPS stimulation of macrophages cultivated in DMEM media with 400 μM of L-arginine. As expected, incubation of RAW 264.7 cells with LPS resulted in a time-dependent accumulation of nitrites and expression of iNOS protein (Figure 2(a)). The expression of iNOS started approximately 4 h after the RAW 264.7 cells were stimulated with LPS and was followed by a gradual nitrite accumulation in cell supernatants (Figure 2(a)). iNOS expression reached its maximum levels 6 h after LPS administration and then remained stable till the end of the experiment. Interestingly, detailed analysis showed that incubation of RAW 264.7 cells with LPS also resulted in a time-dependent production of O2, which started to rise early (approx., 3 h after LPS administration) and was stable for the next few hours. Then we observed a massive increase in O2 formation (Figure 2(a)). The protein concentration of the total cellular mass had not significantly changed in any of the experimental groups, in comparison with the control cells. This indicates that none of the studied drugs was toxic for RAW 264.7 in the concentrations applied (data not shown).

3.3. L-Arginine-Enhanced Production of O2 Was Not Associated with Changes in NADPH Oxidase Expression and Activity

Since NADPH oxidase is known to be the principal source of O2 in activated phagocytes, we determined whether the changes in O2 production observed during the time of macrophage activation were associated with an increased expression of the selected NADPH oxidase subunits. Using the quantitative RT-PCR method, we showed that LPS significantly increased only the mRNA levels of the NOX2 membrane-associated complex (Figure 2(b)), with the levels of cytosolic p47 and p67 subunits remaining unaffected (Figure 2(b)). Importantly, extracellular L-arginine supplementation did not change the mRNA levels of all subunits in nonstimulated and LPS-stimulated RAW 264.7 cells (Figure 2(b)). To study the activity of NADPH oxidase in macrophages and cell lysates, we used two known activators of oxidative burst, PMA and OZP. We found that the PMA- and OZP-induced O2 formation was not affected by L-arginine in the concentrations applied (0–400 μM) (data not shown).

3.4. L-Arginine-Enhanced Production of O2 Was Dependent on iNOS Expression in RAW 264.7 Macrophages

To further define the role of iNOS enzyme in the regulation of L-arginine-dependent O2 production, we established stabile RAW 264.7 cell clones transfected with shRNA against iNOS (iNOS−/− RAW 264.7 cells). In contrast to LPS-stimulated RAW 264.7, successfully transfected iNOS−/− RAW 264.7 cells were characterized by downregulated iNOS protein expression (Figure 3(a)). Correspondingly, the nitrite accumulation in RAW 264.7 cell supernatants was significantly higher after 24-hour stimulation with LPS, in comparison with the basal level of nitrites in nonstimulated RAW 264.7, while no such increase was observed in iNOS−/− RAW 264.7 cell supernatants. Interestingly, a similar effect was determined for O2 production, which was significantly reduced in iNOS−/− RAW 264.7 cells stimulated with LPS (Figure 3(b)).

Further, we analyzed whether the NADPH oxidase activity in iNOS−/− RAW 264.7 cells can be affected by the downregulation of iNOS protein expression. We used PMA and OZP for activation of nonstimulated and LPS-stimulated macrophages in the presence of 400 μM L-arginine. We found that treatment of RAW 264.7 and iNOS−/− RAW 264.7 cells with either PMA or OZP resulted in comparable changes in O2 formation, represented as an increased reduction of cytochrome c (Figures 3(c) and 3(d)). However, when RAW 264.7 cells were exposed to LPS for 24 h, PMA- and OZP-induced O2 production was significantly potentiated, in comparison to iNOS−/− RAW 264.7 cells where no such increase was observed. Therefore, we concluded that downregulation of iNOS protein expression did not directly influence the activation of NADPH oxidase.

Increased NOS-dependent O2 formation led to a question of whether the amount of nitrotyrosines reflects the production of ONOO in macrophages. While LPS-treated RAW 264.7, together with RAW 264.7 cells transfected with the negative control plasmid, showed intensive staining for nitrotyrosines, we found no effect for iNOS−/− RAW 264.7 cells stimulated with LPS (Figure 4). Interestingly, pretreatment of LPS-stimulated RAW 264.7 cells with L-NAME (25 μM) led to a remarkable decrease in the immunostaining for nitrotyrosines (Figure 4(c)).

3.5. NOS Inhibitors Regulate NO and O2 Production in LPS-Stimulated RAW 264.7 Macrophages

To verify our hypothesis that an increase in O2 formation was associated with the activity of the iNOS enzyme, we used different NOS inhibitors (AMT, 10 μM; AG, 10 μM; L-NAME, 25 μM; LYS, 10 μM). None of the studied drugs was toxic for RAW 264.7 in the concentrations applied (data not shown). First, we tested the effects of inhibitors on iNOS protein expression and iNOS-derived NO production for 24 h. The exposure of LPS-stimulated RAW 264.7 cells to AMT, AG, L-NAME, and LYS caused a significant inhibition of nitrite formation in cell supernatants, while iNOS protein expression was not changed (Figure 5(a)). In control experiments, we found that none of the NOS inhibitors tested were able to induce iNOS protein expression or nitrite accumulation in nonstimulated RAW 264.7 cells incubated in the presence of 400 μM L-arginine (data not shown).

To confirm that O2 was generated by iNOS, cells were pretreated with NOS inhibitors in the two time-points chosen, according to the results shown in Figure 2. NOS inhibitors administered together with LPS had no effect on O2 production within the first 10 h of incubation (Figure 5(b)). In contrast, after 15 h of incubation, more than 70% of O2 production was blocked by all of the NOS inhibitors used (Figure 5(b)). Furthermore, the NOS inhibitors did not affect NADPH-oxidase-derived O2 production in PMA- or OZP-activated RAW 264.7 cells incubated with 400 μM L-arginine in the absence of LPS (data not shown).

3.6. BH4 Is Able to Suppress L-Arginine-Induced NO and O2 Production in RAW 264.7 Cells

According to data published by Kuzkaya et al. [33], we expected that the uncoupled state of iNOS induced by increased extracellular L-arginine concentrations in LPS-stimulated RAW 264.7 cells could be caused by the decreasing levels of BH4 during the time of the experiments. We added an additional 10 μM of BH4 to the cultured media with 400 μM L-arginine, along with LPS (50 ng/mL) stimulation. We showed that the treatment of RAW 264.7 cells with BH4 had no effect on nitrite accumulation and O2 production after 10 h of incubation with LPS (data not shown); however, it was able to partially prevent a massive increase in O2 production after 24 h of incubation with LPS (Figure 6). Accordingly, treatment of RAW 264.7 cells with BH4 caused an increase in nitrite accumulation after 24 h of cell incubation with LPS, and the iNOS protein expression remained unaffected (Figure 6).


4. DISCUSSION

The current data clearly demonstrate that, beside the regulation of NO production, L-arginine is able to cause a dose- and time-dependent increase in iNOS-derived O2 formation in inflammatory macrophages. Our findings are important with respect to the fact that activation and/or accumulation of macrophages can significantly contribute to the development of inflammation, as well as many disease states that have been shown to be associated with impaired L-arginine metabolism and reduced L-arginine plasma levels (e.g., asthma, pulmonary hypertension, cytstic fibrosis, and renal failure) [3439].

At present, NADPH oxidase is still considered the main source of O2 in inflammatory macrophages [7]. Importantly, it was demonstrated previously that iNOS derived from macrophages is capable of generating functionally important levels of O2, in addition to NO generation under conditions of L-arginine or cofactors depletion [14, 15]. In contrast, we demonstrated that downregulation of iNOS protein expression leads to a marked reduction of O2 production in LPS-stimulated macrophages which are exposed to 400 μM of extracellular L-arginine. We found that, under inflammatory conditions, the activity of iNOS enzyme significantly contributes to O2 production after 15 hours of incubation of the macrophages with LPS. Importantly, O2 production was potentiated by an increased extracellular L-arginine concentration. From these observations, several questions arise. (a) Is the increased O2 formation associated with changes in NADPH-oxidase expression or activity? (b) Is there any time consistency between O2 formation, iNOS protein expression, and iNOS-dependent NO production? (c) Is iNOS probably responsible for increased O2 formation?

According to our presented data, we came up with the following possible explanations. First, the NOS inhibitors used in this study could have scavenging properties against ROS and NO. This explanation can be refused, because no scavenging properties of the NOS inhibitors were found in our study. The second alternative is that NOS inhibitors or L-arginine alone may regulate the NADPH oxidase-dependent production of O2. However, we demonstrated that none of the tested compounds affected O2 production from NADPH oxidase in macrophages activated with PMA or OZP in the absence of LPS. The third possibility, that L-arginine regulated the expression of NADPH oxidase in LPS-stimulated macrophages, was also disproved, because the treatment of RAW 264.7 cells with a different extracellular L-arginine concentration had no effect on the NOX2, p47, and p67 mRNA levels. Finally, after the series of experiments with iNOS−/− RAW 264.7 macrophages and NOS inhibitors, we proved our assumption that the massive increase in O2 formation was very likely caused by macrophage iNOS “uncoupling.”

As demonstrated by our study, increased L-arginine concentrations actively contribute to the uncoupled state of iNOS. In contrast, Xia et al. [14, 15], in both of their studies, presented that a depletion of cytosolic L-arginine triggered O2 generation from macrophage iNOS. Xia et al. [14] also showed that increased O2 production can be followed by an NOS-dependent ONOO formation. They suggest that by coupling L-arginine levels to iNOS protein synthesis, macrophages provide a mechanism for ensuring that iNOS is not expressed in L-arginine-depleted cells and that toxic O2 cannot be produced. Based on these data, other clinical studies suggested that limited L-arginine levels can be the significant source of O2- as well as ONOO-mediated tissue injury [34, 36, 37, 40]. Compared to our results, there arises an important question regarding the possibility that the lack of L-arginine is responsible for the macrophage ONOO formation. Our data and data published by others [41, 42] implicate that when L-arginine is not available for the iNOS, there is no NO production in stimulated macrophages and thus NO cannot react with O2 to form ONOO. Therefore, it is questionable if iNOS-derived ONOO can be responsible for the increased nitrotyrosine formation in macrophages activated in L-arginine-free media as demonstrated by Xia et al. [14, 15]. Further, Xia et al. [14] did not detect O2 production by macrophages incubated with LPS and IFN-γ in the presence of L-arginine supplemented media after 24 h. In contrast, in our experiments, the LPS-induced O2 formation could be detected by at least two different methodological approaches as presented above. Interestingly, the only difference between our study and study of Xia et al. [14, 15] is costimulation of macrophages by IFN-γ. The combination of LPS and IFN-γ was used for macrophage stimulation by other authors evaluating O2 and ONOO production by macrophages [42, 43]. Amatore et al. [42] described that NO production between 8–18 h after cell stimulation was slight, and a strong linear increase was then observed for a period of 18–48. Similarly in our experiments, the beginning of gradual NO production was detected after 6 h of macrophage incubation with LPS. Further, Amatore et al. [42] discovered that macrophages produced ONOO after 18 h of incubation with both stimulators, which is in accordance with our data.

We suggest that, during the time of macrophage activation with LPS, L-arginine is consumed by iNOS enzyme, resulting in the production of NO. Because NADPH oxidase in macrophages produces a relevant amount of O2 during the first hours after stimulation with LPS, it can easily react with iNOS-derived NO and form highly reactive ONOO. The more L-arginine that is present, the more ONOO that is produced. Because ONOO is a powerful oxidant, it is able to readily oxidize BH4, which can lead to the formation of the BH3 radical. This phenomenon was already described in endothelial culture cells and vessels, where these conditions caused eNOS uncoupling. Interestingly, after exposure of endothelial cells to ONOO, eNOS activity could be fully restored by treating the cells with exogenous BH4 [33]. Our hypothesis that the same conditions might play an important role in iNOS uncoupling was supported by the fact that supplementation of BH4 to the cultured and LPS-stimulated macrophages partially prevented an increase in O2 formation after prolonged incubation with LPS.

Our findings have some important implications. We have shown that LPS is able to biphasically induce O2 production in RAW 264.7 cells. In the first few hours after LPS-stimulation, macrophages produce a relatively small but significant amounts of O2 which should be considered as being formed by activated NADPH oxidase. In the second phase, LPS causes a massive increase in O2 production, predominantly due to iNOS uncoupling. More importantly, the second phase of O2 production is directly controlled by extracellular L-arginine availability.

In conclusion, the L-arginine availability seems to play a critical role for the immune state of macrophages and there are now two sides of this problematic. One is that a lack of extracellular L-arginine is responsible for the attenuation of immune functions associated with the decrease in immune cell proliferation and NO production, which can lead to different pathophysiological states [4448]. On the other side, supplementation by L-arginine could lead to an increased O2, and subsequently an increased ONOO formation that is critical for host defense but might also be deleterious for host cells/tissue.


ACKNOWLEDGMENTS

The authors thank Lenka Vystrcilova for excellent technical assistance and the BioScience Writters for their expert grammar analysis. This work was conducted under the research plans (AVOZ50040507 and AVOZ50040702) and supported by the Czech Science Foundation (524/08/1753), Masaryk University in Brno (MUNI/C/0886/2010), and European Regional Development Fund-Project FNUSA-ICRC (no. CZ.1.05/1.1.00/02.0123).


References
1. Cohen J. The immunopathogenesis of sepsisNatureYear: 2002420691788589112490963
2. Chait A,Chang YH,Oram JF,Heinecke JW. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?Journal of Lipid ResearchYear: 200546338940315722558
3. Pickup JC,Crook MA. Is type II diabetes mellitus a disease of the innate immune system?DiabetologiaYear: 19984110124112489794114
4. Erickson B,Sperber K,Frishman WH. Toll-like receptors: new therapeutic targets for the treatment of atherosclerosis, acute coronary syndromes, and myocardial failureCardiology in ReviewYear: 200816627327918923230
5. Victor VM,Rocha M,de La Fuente M. Immune cells: free radicals and antioxidants in sepsisInternational ImmunopharmacologyYear: 20044332734715037211
6. Zhao X,Carnevale KA,Cathcart MK. Human monocytes use Rac1, not Rac2, in the NADPH oxidase complexThe Journal of Biological ChemistryYear: 200327842407884079212912997
7. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages. Contribution to atherosclerosisArteriosclerosis, Thrombosis, and Vascular BiologyYear: 20042412328
8. Moncada S,Palmer RMJ,Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacologyPharmacological ReviewsYear: 19914321091421852778
9. Linton MF,Fazio S. Macrophages, inflammation, and atherosclerosisInternational Journal of ObesityYear: 2003273S35S4014704742
10. Guha M,Mackman N. LPS induction of gene expression in human monocytesCellular SignallingYear: 2001132859411257452
11. Boscá L,Zeini M,Través PG,Hortelano S. Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fateToxicologyYear: 2005208224925815691589
12. Nishida CR,Ortiz de Montellano PR. Electron transfer and catalytic activity of nitric oxide synthases. Chimeric constructs of the neuronal, inducible, and endothelial isoformsThe Journal of Biological ChemistryYear: 199827310556655719488682
13. Andrew PJ,Mayer B. Enzymatic function of nitric oxide synthasesCardiovascular ResearchYear: 199943352153110690324
14. Xia Y,Dawson VL,Dawson TM,Snyder SH,Zweier JL. Nitric oxide synthase generates Superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injuryProceedings of the National Academy of Sciences of the United States of AmericaYear: 19969313677067748692893
15. Xia Y,Zweier JL. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophagesProceedings of the National Academy of Sciences of the United States of AmericaYear: 19979413695469589192673
16. Sullivan JC,Pollock JS. Coupled and uncoupled NOS: separate but equal? Uncoupled NOS in endothelial cells is a critical pathway for intracellular signalingCirculation ResearchYear: 200698671771916574911
17. Flynn NE,Meininger CJ,Haynes TE,Wu G. The metabolic basis of arginine nutrition and pharmacotherapyBiomedicine and PharmacotherapyYear: 2002569427438
18. Wu G,Bazer FW,Davis TA,et al. Arginine metabolism and nutrition in growth, health and diseaseAmino AcidsYear: 200937115316819030957
19. Li P,Yin YL,Li D,Kim WS,Wu G. Amino acids and immune functionBritish Journal of NutritionYear: 200798223725217403271
20. Wu G,Morris SM Jr.. Arginine metabolism: nitric oxide and beyondBiochemical JournalYear: 199833611179806879
21. Bronte V,Zanovello P. Regulation of immune responses by L-arginine metabolismNature Reviews ImmunologyYear: 200558641654
22. Peranzoni E,Marigo I,Dolcetti L,et al. Role of arginine metabolism in immunity and immunopathologyImmunobiologyYear: 20082129-1079581218086380
23. Kirk SJ,Hurson M,Regan MC,et al. Arginine stimulates wound healing and immune function in elderly human beingsSurgeryYear: 199311421551608342121
24. Barbul A,Lazarou SA,Efron DT,Wasserkrug HL,Efron G. Arginine enhances wound healing and lymphocyte immune responses in humansSurgeryYear: 199010823313372382229
25. Grasemann H,Schwiertz R,Grasemann C,Vester U,Racké K,Ratjen F. Decreased systemic bioavailability of L-arginine in patients with cystic fibrosisRespiratory ResearchYear: 20067, article 87
26. Konopka R,Hýžďalová M,Kubala L,Pacherník J. New luminescence-based approach to measurement of luciferase gene expression reporter activity and adenosine triphosphate-based determination of cell viabilityFolia BiologicaYear: 2010562667120492758
27. Schwedhelm E,Xanthakis V,Maas R,et al. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham Offspring CohortClinical ChemistryYear: 20095581539154519541865
28. Pekarova M,Kralova J,Kubala L,et al. Continuous electrochemical monitoring of nitric oxide production in murine macrophage cell line RAW 264.7Analytical and Bioanalytical ChemistryYear: 200939451497150419430767
29. Pekarova M,Kralova J,Kubala L,et al. Carvedilol and adrenergic agonists suppress the lipopolysaccharide-induced no production in raw 264.7 macrophages via the adrenergic receptorsJournal of Physiology and PharmacologyYear: 200960114315019439816
30. Rudolph TK,Rudolph V,Edreira MM,et al. Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient miceArteriosclerosis, Thrombosis, and Vascular BiologyYear: 2010305938945
31. Viačková D,Pekarová M,Crhák T,et al. Redox-sensitive regulation of macrophage-inducible nitric oxide synthase expression in vitro does not correlate with the failure of apocynin to prevent lung inflammation induced by endotoxinImmunobiologyYear: 2011216445746521093096
32. Ambrozova G,Pekarova M,Lojek A. The effect of lipid peroxidation products on reactive oxygen species formation and nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 macrophagesToxicology in VitroYear: 201125114515220940037
33. Kuzkaya N,Weissmann N,Harrison DG,Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthaseThe Journal of Biological ChemistryYear: 200327825225462255412692136
34. King NE,Rothenberg ME,Zimmermann N. Arginine in asthma and lung inflammationJournal of NutritionYear: 2004134102830S2836S15465795
35. Morris CR,Poljakovic M,Lavrisha L,Machado L,Kuypers FA,Morris SM. Decreased arginine bioavailability and increased serum arginase activity in asthmaAmerican Journal of Respiratory and Critical Care MedicineYear: 2004170214815315070820
36. Morris CR. New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapyTreatments in Respiratory MedicineYear: 200651314516409014
37. Gokce N. L-arginine and hypertensionJournal of NutritionYear: 2004134102807S2811S15465790
38. Gornik HL,Creager MA. Arginine and endothelial and vascular healthJournal of NutritionYear: 2004134102880S2887S15465805
39. Cherla G,Jaimes EA. Role of L-arginine in the pathogenesis and treatment of renal diseaseJournal of NutritionYear: 2004134102801S2806S15465789
40. König T,Bogdan C,Schleicher U. Translational repression of inducible NO synthase in macrophages by l-arginine depletion is not associated with an increased phosphorylation of eIF2αImmunobiologyYear: 20092149-1082282719628295
41. El-Gayar S,Thüring-Nahler H,Pfeilschifter J,Röllinghoff M,Bogdan C. Translational control of inducible nitric oxide synthase by IL-13 and arginine availability in inflammatory macrophagesJournal of ImmunologyYear: 2003171945614568
42. Amatore C,Arbault S,Bouton C,Drapier JC,Ghandour H,Koh ACW. Real-time amperometric analysis of reactive oxygen and nitrogen species released by single immunostimulated macrophagesChemBioChemYear: 2008991472148018491327
43. Noda T,Amano F. Differences in nitric oxide synthase activity in a macrophage-like cell line, RAW264.7 cells, treated with lipopolysaccharide (LPS) in the presence or absence of interferon-γ (IFN-γ): possible heterogeneity of iNOS activityJournal of BiochemistryYear: 1997121138469058189
44. Popovic PJ,Zeh HJ,Ochoa JB. Arginine and immunityJournal of NutritionYear: 200713761681S1686S17513447
45. Morris SM. Arginine metabolism: boundaries of our knowledgeJournal of NutritionYear: 200713761602S1609S17513435
46. Coman D,Yaplito-Lee J,Boneh A. New indications and controversies in arginine therapyClinical NutritionYear: 200827448949618640748
47. Wittmann F,Prix N,Mayr S,et al. L-arginine improves wound healing after trauma-hemorrhage by increasing collagen synthesisJournal of TraumaYear: 200559116216816096557
48. Wu G,Meininger CJ. Arginine nutrition and cardiovascular functionJournal of NutritionYear: 2000130112626262911053497

Article Categories:
  • Research Article

Keywords: Macrophages, L-arginine, inducible nitric oxide synthase, superoxide anion, NO..

Previous Document:  A monitoring network on acidification in Flanders, Belgium.
Next Document:  Of toasters and molecular ticker tapes.